Report : Asia Pacific Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)
Prothrombin Complex Concentrates Segment has the Largest Share of Product in the Asia Pacific Anticoagulant Reversal Drug Market during 2020–2027
According to a new market research study on “Asia Pacific Anticoagulant Reversal Drug Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Product, and Distribution Channel,” is expected to reach US$ 444.8 million by 2027 from US$ 173.5 million in 2019. The market is estimated to grow at a CAGR of 13.2% from 2019 to 2027. The report provides trends prevailing in the Asia Pacific anticoagulant reversal drug market along with the drivers and restraints pertaining to the market growth. The rise in the prevalence of atrial fibrillation (AFiB) and an increase in prevalence of stroke are drivers growing the Asia Pacific anticoagulant reversal drug market. However, the market is expected experiencing slow growth during the forecast period owing to the high cost of anticoagulant reversal drugs.
The market for anticoagulant reversal drug market is segmented into product, and application. Based on product, the market is segmented into prothrombin complex concentrates, vitamin K, andeXXa, protamine, idarucizumab, and tranexamic acid. In 2019, the prothrombin complex concentrates accounted for the largest share and is expected to grow due to increasing demand. It is widely accepted as a reliable and fast alternative to fresh frozen plasma to control excessive bleeding as it has properties to reverse the effects of oral anticoagulant treatments. On the other hand, idarucizumab is expected to grow at the fastest CAGR during the forecast period.
Boehringer Ingelheim International GmbH, Pfizer Inc, Octapharma AG, Fresenius Kabi AG, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), CSL Limited, and Grifols, S.A., China Biologic Products, Inc., and Shanghai RAAS Blood Products Co., Ltd. are among the leading companies in the Asia Pacific anticoagulant reversal drug market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in November 2020, B. Braun Melsungen AG and Grifols form strategic alliance to offer integrated solutions for safe automated drug preparation and administration.
The report segments the Asia Pacific Anticoagulant Reversal Drug market as follows:
- Prothrombin Complex Concentrates
- Vitamin K
- Tranexamic Acid
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Asia Pacific
- South Korea
- Rest of Asia Pacific
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org